Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03239145 · OUTCOME

Median Time To Progression (TTP)

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
90% Confidence Interval
Time frame
Median follow-up was 29.3 months (range 0.9 - 42.0 months).

What was measured

TTP based on Kaplan-Meier method is defined as the time from registration to progression disease (PD), or censored at date of last disease evaluation for those without progression reported. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

Analysis population: The analysis population will include patients enrolled in the dose escalation and dose expansion portions of the trial. Per protocol, the dose escalation and dose expansion data may be combined for patients with the same cancer type who received the same treatment doses.

Groups in this outcome

[Dose Level II] Pembrolizumab + Trebananib (Colorectal)

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.

[Dose Level II] Pembrolizumab + Trebananib (Ovarian)

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.

[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
[Dose Level II] Pembrolizumab + Trebananib (Colorectal)40
[Dose Level II] Pembrolizumab + Trebananib (Ovarian)11
[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)4

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
[Dose Level II] Pembrolizumab + Trebananib (Colorectal)3.1Not reported2.83.2Not reported
[Dose Level II] Pembrolizumab + Trebananib (Ovarian)3.1Not reported3.03.8Not reported
[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)4.4Not reported1.2NAThe upper bound of the TTP 90% confidence interval was not reached due to insufficient events at the time of analysis.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.8
        upper Limit
        3.2
        value
        3.1
      2. group Id
        OG001
        lower Limit
        3.0
        upper Limit
        3.8
        value
        3.1
      3. comment
        The upper bound of the TTP 90% confidence interval was not reached due to insufficient events at the time of analysis.
        group Id
        OG002
        lower Limit
        1.2
        upper Limit
        NA
        value
        4.4
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    2. group Id
      OG001
      value
      11
    3. group Id
      OG002
      value
      4
    units
    Participants
description
TTP based on Kaplan-Meier method is defined as the time from registration to progression disease (PD), or censored at date of last disease evaluation for those without progression reported. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.
dispersion Type
90% Confidence Interval
groups
  1. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.
    id
    OG000
    title
    [Dose Level II] Pembrolizumab + Trebananib (Colorectal)
  2. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.
    id
    OG001
    title
    [Dose Level II] Pembrolizumab + Trebananib (Ovarian)
  3. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.
    id
    OG002
    title
    [Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)
param Type
MEDIAN
population Description
The analysis population will include patients enrolled in the dose escalation and dose expansion portions of the trial. Per protocol, the dose escalation and dose expansion data may be combined for patients with the same cancer type who received the same treatment doses.
reporting Status
POSTED
time Frame
Median follow-up was 29.3 months (range 0.9 - 42.0 months).
title
Median Time To Progression (TTP)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice